Fumihiko Sakai

Publication Activity (10 Years)

Years Active: 2021-2022
Publications (10 Years): 4

Top Topics

End Stage Renal Disease

Randomized Controlled Trial

Ejection Fraction

Top Venues

Neurology and therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Yasuhiko Matsumori, Mika Komori, Yuka Tanji, Akichika Ozeki, Fumihiko Sakai
Rapid Onset and Sustained Efficacy of Lasmiditan Among Japanese Patients with Migraine: Prespecified Analyses of a Randomized Controlled Trial. Neurology and therapy 11 (4) (2022)
Fumihiko Sakai, Norihiro Suzuki, Byung-Kun Kim, Yoshihisa Tatsuoka, Noboru Imai, Xiaoping Ning, Miki Ishida, Kaori Nagano, Katsuhiro Iba, Hiroyuki Kondo, Nobuyuki Koga
Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache 61 (7) (2021)
Fumihiko Sakai, Norihiro Suzuki, Xiaoping Ning, Miki Ishida, Chiharu Usuki, Katsuhiro Iba, Yuki Isogai, Nobuyuki Koga
Long-Term Safety and Tolerability of Fremanezumab for Migraine Preventive Treatment in Japanese Outpatients: A Multicenter, Randomized, Open-Label Study. Drug safety 44 (12) (2021)
Fumihiko Sakai, Norihiro Suzuki, Byung-Kun Kim, Hisaka Igarashi, Koichi Hirata, Takao Takeshima, Xiaoping Ning, Tomoko Shima, Miki Ishida, Katsuhiro Iba, Hiroyuki Kondo, Nobuyuki Koga
Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache 61 (7) (2021)